In this Healio Video Perspective from Retina 2026, Ehsan Rahimy, MD, discusses the potential of IL-6 inhibition for the ...
Eye drop nanoparticles that shrink over time overcome the eye's natural defenses, delivering protein drugs to the retina and ...
Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...
Manufacturing differences between ranibizumab and aflibercept biosimilars might shape pricing, uptake, and patient access globally.
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 ...
Nikkhil K Masurkar Wednesday, January 14, 2026, 08:00 Hrs [IST] Myopia is a widespread vision issue affecting over two ...
As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...
Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
As of December 2025, a total of 90 biosimilars across 20 unique biological molecules had been approved in the United States.
Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results